Homozygous deletions of CDKN2A/B emerge as potent biomarkers in gliomas, leading to uncontrolled cell cycle activity and increased cell proliferation [34], (Fig. S1 in Additional file 1). The gene discussed is CDKN2A; the disease is glioma.